/주식/AURA
AURA

AURA

USD

Aura Biosciences Inc. Common Stock

$6.630-0.460 (-6.488%)

실시간 가격

Healthcare
생명공학
미국

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$7.090

고가

$7.120

저가

$6.615

거래량

0.16M

기업 기본 정보

시가총액

411.1M

산업

생명공학

국가

United States

거래 통계

평균 거래량

0.30M

거래소

NGM

통화

USD

52주 범위

저가 $4.345현재가 $6.630고가 $12.378

관련 뉴스

Analyst Upgrades

HC Wainwright & Co. Assumes Aura Biosciences at Buy, Announces Price Target of $22

HC Wainwright & Co. analyst Andres Maldonado assumes Aura Biosciences with a Buy rating and announces Price Target of $22.

더 보기
HC Wainwright & Co. Assumes Aura Biosciences at Buy, Announces Price Target of $22
Analyst Upgrades

JMP Securities Reiterates Market Outperform on Aura Biosciences, Maintains $19 Price Target

JMP Securities analyst Jonathan Wolleben reiterates Aura Biosciences with a Market Outperform and maintains $19 price target.

더 보기
JMP Securities Reiterates Market Outperform on Aura Biosciences, Maintains $19 Price Target
GlobeNewswire

Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants

BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. ("Aura") (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today

더 보기
Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants
GlobeNewswire

Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants

BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. ("Aura") (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today

더 보기
Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants
GlobeNewswire

Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights

First Patient Enrolled in Multi-Dose Phase 1b/2 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer (NMIBC); Initial Data at 3 Months Expected by Year-End 2025 Strengthened Leadership Team with the Appointment of

더 보기
Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights